Postpartum depression can have lasting consequences for the mother, child and family. Maternal mental health is a critical public health component of perinatal care and maternal safety. One in four at-risk women may experience depression symptoms after each birth. The grant will support the expansion of the program and help researchers determine if all pregnant women or only those at high risk should be given the opportunity to participate. Five clinical trials have shown that ROSE prevents half of the cases of postpartum depression among at-risk women. ROSE is a four-session class given to moms at risk of postpartum depression. “If we find the expanded intervention is effective, we can work to scale up the program, strengthen families while supporting moms, and reduce costs within the healthcare system,” she said. Zlotnick is also a Professor of Psychiatry at Brown University and Director of Women’s Health Research at the Care New England Health System. “This will be the first study to look at the effectiveness of postpartum depression among a general population of women and women screening negative for postpartum depression risk ,” said Caron Zlotnick, PhD, one of two principal investigators on the grant. ROSE stands for “ Reach Out, Stand Strong, Essentials for New Mothers. The grant is officially titled “The ROSE Scale-Up Study: Informing a decision about ROSE as universal postpartum depression prevention. Researchers from Henry Ford Health, Michigan State University and Care New England Health System are collaborating on a $6.2 million mental health research grant from the National Institutes of Health to expand and further research a postpartum depression intervention and prevention program that is proven to save lives.

Rose stimulator